Axelar kicks off Phase I/II trial of brain tumor drug

01/22/2013 | Pharmaceutical Business Review Online

Swedish firm Axelar began a Phase I/II trial to assess the efficacy of its investigational drug, AXL1717, in patients with relapsed or progressive malignant astrocytomas. The oral insulin-like growth factor 1 receptor pathway inhibitor is also undergoing a midstage trial for nonsmall-cell lung cancer.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ